Literature DB >> 7276137

Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation.

L V Rubinstein, M H Gail, T J Santner.   

Abstract

Mesh：

Year:  1981        PMID： 7276137     DOI： 10.1016/0021-9681(81)90007-2

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  33 in total

1.  Duration of accrual and follow-up for two-stage clinical trials.

Authors:  L D Case; T M Morgan
Journal:  Lifetime Data Anal       Date:  2001-03       Impact factor: 1.588

2.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

Review 3.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

4.  A randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) Study.

Authors:  Cynthia A Thomson; Tracy E Crane; Austin Miller; David O Garcia; Karen Basen-Engquist; David S Alberts
Journal:  Contemp Clin Trials       Date:  2016-07-06       Impact factor: 2.226

5.  Milestone prediction for time-to-event endpoint monitoring in clinical trials.

Authors:  Fang-Shu Ou; Martin Heller; Qian Shi
Journal:  Pharm Stat       Date:  2019-02-26       Impact factor: 1.894

6.  Optimal two-stage log-rank test for randomized phase II clinical trials.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2016-04-06       Impact factor: 1.051

7.  Single-arm Phase II cancer survival trial designs.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

Review 8.  A comparison of phase II study strategies.

Authors:  Sally Hunsberger; Yingdong Zhao; Richard Simon
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 9.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE).

Authors:  Mark Nelson; Christopher Reid; Lawrence Beilin; Geoffrey Donnan; Colin Johnston; Henry Krum; Elsdon Storey; Andrew Tonkin; John McNeil
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.